Far upstream element-binding protein 1 facilitates hepatocellular carcinoma invasion and metastasis

Author:

Fu Pei-Yao1ORCID,Hu Bo1,Ma Xiao-Lu2,Tang Wei-Guo3,Yang Zhang-Fu1,Sun Hai-Xiang1,Yu Min-Cheng1,Huang Ao1,Hu Jin-Wu1,Zhou Chen-Hao1,Fan Jia1,Xu Yang1,Zhou Jian1456

Affiliation:

1. Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China

2. Laboratory Medicine Department, Shanghai Tumor Center of Fudan University, Shanghai, P.R. China

3. Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai, P.R. China

4. State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China

5. Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China

6. Institute of Biomedical Sciences, Fudan University, Shanghai, China

Abstract

AbstractPrevious research suggests that far upstream element-binding protein 1 (FUBP1) plays an important role in various tumors including epatocellular carcinoma (HCC). However, the role of FUBP1 in liver cancer remains controversial, and the regulatory pathway by FUBP1 awaits to be determined. This study aims to identify the role of FUBP1 in HCC progression. Our result shows that the high level of FUBP1 expression in HCC predicts poor prognosis after surgery. Overexpression of FUBP1 promotes HCC proliferation, invasion, and metastasis by activating transforming growth factor-β (TGF-β)/Smad pathway and enhancing epithelial-mesenchymal transition (EMT) in vitro and in vivo. Inhibitor of Thrombospondin-1 (LSKL) could inhibit HCC proliferation and invasion in vitro and in vivo by blocking the activation of TGF-β/Smad pathway mediated by thrombospondin-1 (THBS1). Our study identified the critical role of FUBP1-THBS1-TGF-β signaling axis in HCC and provides potentially new therapeutic modalities in HCC.

Funder

National Science and Technology Major Project

“Sailing Program” of Shanghai Science and Technology Committee

National Natural Science Foundation of China

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3